Global Neurogenic Bladder Infections Market – Industry Trends and Forecast to 2029

Market Analysis and Insights

The market is expected to experience tremendous growth within the forecast period as there will be an increase in prevalence of the associated diseases, which generally affects millions of people around the world, though it is more common in the elderly. Moreover, the market is expected to show a negative growth within the forecast period due to the effects of restrictions caused by sudden outbreak of COVID-19.

• Data Bridge Market Research analyses that the neurogenic bladder infections market will grow at a CAGR of 2.70% during the forecast period of 2022 to 2029. The “quinolones” accounts for the largest drug type segment in the neurogenic bladder infections market within the forecasted period.

Market Definition

The neurogenic bladder infections are associated with urinary problems in which people lose bladder control as a result of spinal cord, brain, and nerve problems, which can lead to multiple diseases like multiple sclerosis, Parkinson’s disease, and others. Urinary bladder dysfunction caused by neurologic dysfunction caused by internal or external trauma, disease, or injury is referred to as neurogenic bladder.

Neurogenic Bladder Infections Market Dynamics

Drivers

• Growing Cases of Chronic Diseases

The growing incidence of diabetes and kidney stones diseases will result in the expansion of the growth rate of the treatment market.

Moreover, the increase in healthcare expenditure and growing geriatric population are also the growth determinants which bolster the growth of the market. Also, the robust pipeline that leads to potential drugs and availability of treatment options will further enhance the growth of neurogenic bladder infections market.

Furthermore, advancement in medical technology, rising initiatives to spread awareness regarding the disease and growing government funding are the factors that will expand the neurogenic bladder infections market. Other factors such as increase in the demand for effective treatment procedures will positively impact the neurogenic bladder infections market's growth rate. Additionally, the people of advanced age are more susceptible to the disease and its recurrence will result in the expansion of neurogenic bladder infections market. 

Opportunities

Moreover, the growing research and development activities of in urinary tract infections along with launch of combination treatment medicines and drugs will boost new opportunities for the market's growth rate. Also, the developments in healthcare technology will escalate the growth rate neurogenic bladder infections market in future.

Restraints/Challenges

However, the lack of awareness among people pertaining UTI will impede the growth rate of neurogenic bladder infections market. Additionally, the stringent government regulations market growth.

This neurogenic bladder infections market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on neurogenic bladder infections market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

The neurogenic bladder infections are basically the urinary issues under which people lose bladder control as a result of spinal cord, brain, and nerve problems. Neurogenic bladder affects 40–90% of people with multiple sclerosis in the United States.

Neurogenic bladder infections market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Neurogenic Bladder Infections Market

The healthcare and pharmaceutical industries were heavily impacted by the COVID-19. The neurogenic bladder infections market was however affected negatively by the sudden emergence of the COVID-19 as it caused lack of access to health-care facilities for routine treatment and medication administration. The implementation of strict lockdowns and isolation regulations across the globe further complicated the disease management and medication adherence and even further caused delays in the import and export of drugs and medicines for the neurogenic bladder infections.

Recent Developments

• In August 2021, Researchers from California Polytechnic State University have developed a new class of antibiotics that target bacterial iron acquisition in urinary tract infections.

Global Neurogenic Bladder Infections Market Scope

The neurogenic bladder infections market is segmented on the basis of type, drug type, test type and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Overactive
• Underactive

On the basis of type, neurogenic bladder infections market is segmented into overactive and underactive.

Drug Type

• Sulphonamides
• Azoles and Amphotericin B
• Tetracycline
• Nitrofurans
• Aminoglycoside Antibiotics
• Cephalosporin
• Quinolones
• Penicillin and Combinations

On the basis of drug type, neurogenic bladder infections market is segmented into sulphonamides, azoles and amphotericin b, tetracycline, nitrofurans, aminoglycoside antibiotics, cephalosporin, quinolones and penicillin and combinations. Aminoglycoside antibiotics have been further segmented into amikacin and gentamicin. Cephalosporins have been further segmented into ceftriaxone, cefuroxime, cefixime and cephalexin. Quinolones have been further segmented into ciprofloxacin, levofloxacin, nalidixic acid, norfloxacin and others. Penicillin and combinations have been further segmented into amoxicillin, amoxicillin and clavulanate potassium and others.

Test Type

• Biochemical Urinary Tract Infection
• Microscopic Urinary Tract Infection
• Flow Cytometric Urinary Tract Infection

On the basis of test type, the neurogenic bladder infections market is segmented into biochemical urinary tract infection, microscopic urinary tract infection and flow cytometric urinary tract infection.

Distribution Channel

• Hospital Pharmacies
• Gynaecology and Urology Clinics
• Drug Store
• Retail Pharmacies
• Online Drug Stores

On the basis of distribution channel, the neurogenic bladder infections market is segmented into hospital pharmacies, gynecology and urology clinics, drug store, retail pharmacies and online drug stores.

Neurogenic Bladder Infections Market Regional Analysis/Insights

The neurogenic bladder infections market is analyzed and market size insights and trends are provided by country, type, drug type, test type and distribution channel as referenced above.

The countries covered in the neurogenic bladder infections market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the neurogenic bladder infections market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the widespread awareness about the UTI and availability of treatment facilities in this region.

Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the  increase in growth can be attributed to the rising awareness among people pertaining about UTI and its treatment as well as rapid improvement in the standards healthcare facilities in the region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Neurogenic Bladder Infections Market Share Analysis

The neurogenic bladder infections market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to neurogenic bladder infections market.

Some of the major players operating in the neurogenic bladder infections market are AstraZeneca, Merck & Co., Inc., Pfizer Inc, Celgene Corporation, AKRON, Inc., Instinctif Partners, Abbott, Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc, GlaxoSmithKline plc, Inc., Takeda Pharmaceutical Company Limited, Melinta Therapeutics LLC, Cipla Inc., Sun Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED, Lupin Pharmaceuticals, Inc., and Ingenus among others.

SKU-52357